AbCellera Biologics (ABCL) Income from Continuing Operations (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Income from Continuing Operations came in at 43165000.0 in Q1 2026, up 5.38% YoY from 40959928.14 in Q1 2025, and down 382.56% on a QoQ basis from 8945000.0 in Q4 2025.
AbCellera Biologics (ABCL) Income from Continuing Operations (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Income from Continuing Operations data on file, last reported at 43165000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 5.38% year-over-year to 43165000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 143956000.0 (up 14.24% YoY) and the FY2025 annual result came in at 146412000.0, up 10.1% from the prior year.
- Income from Continuing Operations retreated to 43165000.0 in Q1 2026, from 8945000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 168573000.0 in Q1 2022 to a low of 57119000.0 in Q3 2025.
- A 5-year average of 20018411.76 and a median of 34727000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 224.53% — and 2023, when it tumbled 349.93%.
- Tracing ABCL's Income from Continuing Operations over 5 years: stood at 29893000.0 in 2022, then sank by 57.73% to 47150000.0 in 2023, then rose by 27.44% to 34210000.0 in 2024, then surged by 73.85% to 8945000.0 in 2025, then tumbled by 382.56% to 43165000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 43165000.0 (Q1 2026), 8945000.0 (Q4 2025), and 57119000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | -55.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.43 Mn |
| Mar 31, 2026 | -43.17 Mn |
| Dec 31, 2025 | -8.95 Mn |
| Sep 30, 2025 | -57.12 Mn |
| Jun 30, 2025 | -34.73 Mn |
| Mar 31, 2025 | -45.62 Mn |
| Dec 31, 2024 | -34.21 Mn |
| Sep 30, 2024 | -51.11 Mn |
| Jun 30, 2024 | -36.93 Mn |
| Mar 31, 2024 | -40.61 Mn |
| Dec 31, 2023 | -47.15 Mn |
| Sep 30, 2023 | -28.61 Mn |
| Jun 30, 2023 | -30.53 Mn |
| Mar 31, 2023 | -40.11 Mn |
| Dec 31, 2022 | -29.89 Mn |
| Sep 30, 2022 | 26.62 Mn |
| Jun 30, 2022 | -6.79 Mn |
| Mar 31, 2022 | 168.57 Mn |
| Dec 31, 2021 | 59.95 Mn |
| Sep 30, 2021 | -21.38 Mn |